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harmacogenetics is one of the most exciting and
clinically relevant applications of the enormous strides that
have been made in defining the genetic basis of human
variation. Completion of the human genome project
brought with it the means to catalogue such variation on
a genome-wide basis,and to apply this knowledge to the
clinical context.The core hypothesis underlying pharma-
cogenetics is that genetic factors play a major role in the
well-recognized differences between individuals in
response to medication and susceptibility to adverse
effects.If these genetic factors can be identified and under-
stood,they may serve as predictors to guide clinicians in
tailoring medication to the individual patient.The techno-
logical tools required in order to achieve this objective are
readily available in the form of high-throughput genotyp-
ing systems that allow thousands of individual genotypes
to be generated at costs that are dramatically declining.At
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The core hypothesis underlying pharmacogenetics is that genetic factors play a significant role in the well-recognized
differences between individuals in response to medication and susceptibility to adverse effects. If these genetic fac-
tors can be identified and understood, they may serve as predictors to guide clinicians in tailoring medication to the
individual patient. Recent developments in the field of antipsychotic drug treatment suggest that pharmacogenetics
could play an important role, permitting the use of first-generation antipsychotics (FGAs) for patients in whom the
use of second-generation antipsychotics (SGAs) is limited by efficacy considerations or adverse effects. In this paper,
key issues that need to be taken into consideration in designing and interpreting pharmacogenetic studies of antipsy-
chotic drugs are discussed against the background of data emanating from studies on the genetics of tardive dyski-
nesia (TD), an important adverse effect of FGAs. The issues considered include the advantages and potential pitfalls
of case-control association studies of pharmacogenetic traits, the role of demographic factors such as age and gender,
additive effects of genes, and gene–gene and gene–environment interaction. The prospects for implementation of
pharmacogenetic testing in the clinic are considered in the context of a preliminary model that has been tested for
prediction of susceptibility to TD.   
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:85-94.the same time,great progress has been made in develop-
ing the information technology that is needed in order to
permit efficient access to the vast body of data that is being
deposited in electronic databases on a daily basis.
Psychiatry is a very important candidate area for the
application of pharmacogenetics to clinical practice.
1,2
Response rates to psychotropic drugs are highly variable,
and this includes all the major classes such as antipsy-
chotics,antidepressants,mood stabilizers,and antianxi-
ety agents.In the field of antipsychotics,a major clinical
dilemma is beginning to emerge,with growing recogni-
tion of the important limitations of the second-genera-
tion (SGA) or atypical antipsychotic drugs.Except for
clozapine,there is little evidence to indicate that SGAs
are more effective than the classical, first-generation
antipsychotics (FGAs).This impression has been borne
out by the initial results of the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) study
which showed no therapeutic advantage of the SGAs
risperidone, quetiapine, and ziprasidone over the low-
potency FGA,perphenazine.
3There was a limited advan-
tage of olanzapine, but at the cost of a significantly
greater incidence of weight gain and adverse metabolic
effects.The advantage of SGAs is thought to lie in their
superior side-effect profile,in particular the reduced inci-
dence of extrapyramidal symptoms (EPS) such as dysto-
nia,parkinsonism,and akathisia,and,in the long term,
the substantially smaller risk of tardive dyskinesia (TD).
However,a recent population-based study suggests that
older individuals treated with high-dose SGAs may be at
similar risk of EPS to patients treated with FGAs.
4
The current trend in clinical practice is to eliminate FGAs
as far as possible, and to employ SGAs as the first-line
medication for the treatment of acute schizophrenic psy-
chosis.This trend has not been implemented worldwide
because of economic considerations,given the major price
differences between SGAs and FGAs,and FGAs are still
widely prescribed.The results of recent studies such as
CATIE
3 raise the important consideration that FGAs
may have a place in the treatment of schizophrenia,sub-
ject to appropriate risk-benefit considerations.Predictors
of susceptibility to EPS and TD,in the case of the FGAs,
and to weight gain and metabolic adverse effects,in the
case of SGAs,could radically alter clinical practice,allow-
ing FGAs or SGAs to be prescribed in accordance with
the risk profile of the individual patient.The availability
of predictors of therapeutic response to FGAs and SGAs
would further improve the risk-benefit ratio.Genetic pre-
dictors are highly feasible in this context,and are the focus
of intensive research in the field of psychiatric pharma-
cogenetics.
Genetic factors that influence drug metabolism (phar-
macokinetics) and molecular targets of drug action
(pharmacodynamics) may be implicated separately or
interactively in the pharmacogenetic profile of a patient
in relation to a particular class of drugs. Extensive
research is needed in order to identify the genes
involved,and the precise variants within these genes that
underlie interindividual variability.In the case of phar-
macokinetic factors,the underlying genetic cause is often
a mutation in a single gene, such as a member of the
extended cytochrome P450 family, which is pivotally
involved in the metabolism of psychotropic drugs.
5
Pharmacodynamic targets include receptors or trans-
porters to which the drugs bind.Variants in these genes
are more likely to be of small effect with several differ-
ent loci being involved,each contributing to the pheno-
type to a small and variable degree.This type of poly-
genic effect is difficult to define clinically,and is sensitive
to spurious influences. Most of the pharmacogenetic
effects that are widely relevant are likely to be polygenic,
requiring significant research efforts to generate and
replicate data that will ultimately be clinically useful.
In this paper,we will consider key issues that need to be
taken into consideration in designing and interpreting
pharmacogenetic studies of antipsychotic drugs.
Examples will be given from a series of studies that has
identified several genes involved in susceptibility to TD
in patients treated with FGAs for an extended period.
Case-control association studies in 
pharmacogenetics: advantages and 
potential pitfalls
The classical strategies employed in the search for genes
that predispose to complex phenotypes are linkage and
association.Linkage studies require recruitment of fam-
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Selected abbreviations and acronyms
AIMS Abnormal Involuntary Movements Scale
EPS extrapyramidal symptoms
FGA first-generation antipsychotic
5-HT serotonin
PANSS Positive And Negative Syndrome Scale
SGA second-generation antipsychotic
TD tardive dyskinesiaily units of varying size,and are not practically feasible in
the context of pharmacogenetics.Family-based associa-
tion studies require smaller family units,but they too are
not practical for pharmacogenetics, except for studies
conducted in pediatric populations.Case-control asso-
ciation studies are the most suitable strategy for phar-
macogenetics. Their advantages are considerable, the
most striking being the possibility of recruiting large sam-
ples that have sufficient statistical power to investigate
genetic variants of relatively small effect.Large samples
are particularly important if the effect of more than one
gene is being studied in the same sample,and interactions
among genes and between genes and the environment
are being sought.On the other hand,case-control designs
are notoriously susceptible to the effects of ethnic strat-
ification,which can lead to spurious results.These are due
to a particular allele being enriched in a particular pop-
ulation.If this population is overrepresented in the case
or control group,a spurious finding will result,in which
the allele is erroneously associated with the phenotype.
The nature of the problem is illustrated in Figure 1,
6
which shows the frequency of the gly allele of the
dopamine D3 receptor gene (DRD3) ser9gly polymor-
phism in samples from several populations.These sam-
ples were included in a pooled and meta-analytic study
of the DRD3 ser9gly polymorphism as a risk factor for
TD.
6 Great variability in the frequency of the 9gly allele
in the different samples included in the study is immedi-
ately evident, ranging from 30% to 40% among
Caucasians from different countries,and reaching 80%
among African-Americans.
If the association of the DRD3 gly9 allele with TD were
tested without controlling for ethnicity in this pooled
sample, made up of 317 patients with TD and 463
patients without TD,spurious results could easily arise.
Therefore,a stepwise logistic regression was employed
so as to allow the confounding effects of ethnicity and
also age and gender to be taken into account.TD was sig-
nificantly associated with DRD3 gly9 allele carrier status
(χ
2=4.46,df=1,P=0.04) over and above the effect of eth-
nicity.Similar positive effects were observed when con-
trolling for age and gender (χ
2=5.02,df=1,P=0.02).
6-9A
meta-analysis was performed,which included all the sam-
ples in the pooled analysis,as well as data from additional
published studies. The Mantel-Haenszel pooled odds
ratio (OR) for DRD3 gly9 allele carrier status increasing
susceptibility to TD was 1.33 (95% confidence interval
[CI] 1.04-1.70,P=0.02) (Figure 2).Meta-analyses are less
sensitive to stratification and admixture (unless these are
present in the samples included in the meta-analysis),
since original data are not pooled and the unit of analy-
sis is studies and not individuals.
The findings of our studies of the DRD3 ser9gly poly-
morphism and TD indicate that, when pooled pharma-
cogenetic analyses are conducted on well-characterized
samples,it is possible to control for the potentially arti-
factual effects of ethnicity.This is important, because it
is essential to gather large samples for pharmacogenetic
studies so as to have sufficient statistical power. The
same general strategy was implemented to examine the
association of the serotonin 5-HT2A receptor gene and
TD,
10 and also to examine association of the 5-HT2C
receptor gene with unipolar and bipolar affective disor-
der.
11When using ostensibly homogeneous samples,the
genomic control method may be implemented to rule
out population influences on the markers being stud-
ied.
12 This involves genotyping additional markers that
are putatively unrelated to the phenotype,and these are
used to determine the degree of stratification that is pre-
sent in the sample.
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Figure 1. Frequency of the gly allele of the dopamine D3 receptor
(DRD3) ser9gly polymorphism in eight samples of different
ethnic origin, which were included in a pooled meta-analysis
in which association of the DRD3 ser9gly polymorphism with
susceptibility to tardive dyskinesia (TD) was examined.
6 The
samples from Bonn (n=240), Milan (n=93), Newcastle (n=69),
Nithsdale (n=100), and Vienna (n=61) were all made up of
Caucasians. The Jerusalem sample (n=113) was made up of
subjects of Jewish Ashkenazi (n=66) or non-Ashkenazi (n=47)
origin. There was no difference in gly allele frequency
between the Ashkenazi and non-Ashkenazi subjects. US-
Cauc, Caucasian subjects recruited in the US (n=81); US-AA,
US African-Americans (n=23).
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0.6Demography matters: age-related 
effects of genetic variants
It is often not taken into account that genetic variants
may have differing functional importance depending on
the stage of the life cycle.This is obvious in the case of
genes that predispose to disorders of later life such as
Alzheimer’s disease (although the pathophysiological
effects of variations in these genes may be manifested
long before the clinical threshold is crossed).Similarly,
genes that influence neurodevelopment in utero may be
associated with susceptibility to schizophrenia that only
becomes clinically manifest in late adolescence. Age-
relatedness may also be important in pharmacogenetic
phenotypes.We have observed an age-related association
of two serotonergic genes,the 5-HT2C (HTR2C) and the
5-HT2A receptor (HTR2A) with susceptibility to TD.
13
Our finding with the 5-HT2A receptor has been repli-
cated in a large multicenter study.
10
In an earlier report
13 (Figure 3),we showed that scores on
the Abnormal Involuntary Movements Scale (AIMS,the
hallmark of TD) were significantly related to the ser23
allele of the cys23ser polymorphism of the 5-HT2C recep-
tor gene and to the 102C allele of the T102C polymor-
phism in the 5-HT2A receptor gene, in older but not
younger patients.We sought to replicate this finding the
context of a multicenter study involving 635 patients,256
of whom manifested TD and 379 of whom did not.
10 Our
initial analysis employed stepwise logistic regression as
for our DRD3 study
6 and showed an overall association
of the T102C polymorphism in the 5-HT1A receptor gene
with TD. We then analyzed the younger and older
patients separately. In keeping with our finding in the
Jerusalem sample alone,
13 the T102C polymorphism was
significantly associated with TD in the older patients only
(Figure 4).
10
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Figure 2. Meta-analysis of DRD3 risk allele (gly) among seven of the
groups included in the pooled analysis reported by Lerer et al
6
(the African-American group was excluded because of
skewed distribution) and three other published studies.
7-9 The
size of each plot is proportional to the sample size of each
group. The Mantel-Haenszel pooled odds ratio (OR) is =1.33
(95% confidence interval [CI] 1.04-1.70) and the associated
test of OR=1 is significant (χ
2=5.12, df=1, P=0.02), while the
cumulative pooled OR is 1.52 with z=11.78 and P<0.0001.
The heterogeneity χ
2=16.97, df=9, P=0.049. 
Reproduced from reference 6: Lerer B, Segman RH, Fangerau, et al.
Pharmacogenetics of tardive dyskinesia: Combined analysis of 780
patients supports association with dopamine D3 receptor gene ser9gly
polymorphism.  Neuropsychopharmacology. 2001;27:109-119.
Copyright © Nature Publishing Group 2001.
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Figure 3. Abnormal Involuntary Movements Scale (AIMS) scores accord-
ing to 5-HT2C (HTR2C) receptor (upper panel) and 5-HT2A
(HTR2A) receptor (lower panel) genotype. Scores in younger
patients (<47 years) are shown on the left of each panel and
in older patients (>47 years) on the right of each panel. For
HTR2C: Old cys-cys versus Old cys-ser, P=0.02; versus Old ser-
ser, P=0.001. For HTR2A: Old 102-TT versus Old 102-TC,
P=0.01; versus Old 102-CC, P=0.01. No differences were sig-
nificant in the young groups. 
Reproduced from reference 13: Segman RH, Lerer B. Age and the rela-
tionship of dopamine D3, serotonin 2C and serotonin 2A receptor
genes to abnormal involuntary movements in chronic schizophrenia.
Mol Psychiatry. 2002;7:137–139. Copyright © Nature Publishing
Group 2001.
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12These replicated findings accentuate the importance of
taking into account the possibility that pharmacogenetic
effects may be age-related. Thus, an association first
reported in an older sample may be missed if replication
is sought in a younger sample.This was the case with our
initial report of an association of the T102C polymor-
phism in the 5-HT2A receptor gene with TD,
14 which was
initially not replicated by Basile et al
15 who studied a sam-
ple more than two decades younger than ours.The age
range of the pooled sample studied by Lerer et al
7 was
wide enough to allow replication of the finding in the
older subjects.
Additive and interactive effects of genes
Pharmacogenetic phenotypes (such as treatment out-
come,onset of therapeutic effect,rapidity of response,
and adverse effects) are complex traits to which back-
ground and demographic factors contribute, as well as
factors related to the treatment.The genetic background
is likely to be polygenic,with an as-yet unknown number
of genes contributing a small proportion of the variance.
These genes can be expected to act in different ways.One
model is additive,the assumption being that each gene
contributes cumulatively to the phenotype,and that the
overall risk is a sum of these individual contributions.A
second,more complex model postulates that the effects
of certain genes are conditional on others, implying
gene–gene interaction or epistasis.Under this model,a
specific allele of gene A will confer an effect in the pres-
ence of a specific allele of gene B,but will not confer sus-
ceptibility in its absence.The situation is rendered more
complex by the possibility that haplotypes made up of
two or more variants may contribute additively or inter-
actively to susceptibility.In addition,gene–environment
interaction must also be taken into account.
These considerations are applicable to TD, which is a
complex trait related to drug treatment,to which several
demographic and background factors contribute,most
notably age, and with which several genes have been
associated.As yet,there has been relatively little work in
psychiatric pharmacogenetics on the combined effects of
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Figure 4. Frequency of 102C allele carriers (TC heterozygotes and CC homozygotes) in younger patients (<47 years) with tardive dyskinesia (Y-TD)
(n=96) and without TD (N-TD) (n=215) (left panel) and in older Y-TD (n=159) and N-TD patients (n=164) (right panel). Likelihood ratio
test for TD status predicting T102CC allele carrier status in younger patients (<47 years): χ
2= 0.18, df=2, P=0.60; in older patients (>47
years): χ
2=10.16, df=1, P=0.001.  
Reproduced from reference 10: Lerer B, Segman RH, Tan E-C, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin
2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol. 2005;8:411. Copyright © Cambridge
University Press 2005.
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100genes and on gene-gene interaction.These models have
been tested on a limited basis in the context of suscepti-
bility to TD in samples that we and other investigators
have studied;the scope of such testing is constrained by
the size of the samples.
The additive effects of two genetic variants on suscepti-
bility to TD were first reported by Segman et al.
16 Patients
who carried both the gly9 allele of the DRD3 ser9gly poly-
morphism and the ser23 allele of the 5-HT2C cys23ser
polymorphism showed evidence of an additive effect of
the two risk alleles,both of which had been shown to sep-
arately increase risk for TD.As shown in Figure 5,
16 the
highest AIMS orofacial dyskinesia scores were observed
in patients who carried both mutant risk alleles.
Studying gene–gene interaction and risk for TD,Segman
et al
17 examined the interactive contribution of a T→C
polymorphism in the promoter region of the cytochrome
P450 17α-hydroxylase gene (CYP17) and the ser9gly
polymorphism of DRD3 that was previously shown to be
associated with TD. CYP17 variability could influence
susceptibility to TD because of effects on neuroprotec-
tive capacity or dopamine output through its role in the
conversion of the neurosteroid,pregnanolone,to dehy-
droepiandrosterone (DHEA). A T→C transition (A2
allele) in the 5' promoter region of the CYP17 gene cre-
ates an additional Sp1 type (CCACC box) promoter site,
resulting in a functionally relevant increase in transcrip-
tion rate.
18 Segman et al
17 found that the T→C polymor-
phism was not in itself associated with TD. However,
there was a significant excess of DRD3 gly allele carriers
among carriers of the CYP17 CC genotype with TD com-
pared with those without TD (75.0% vs 14.3%;χ
2=6.0,
df=1,P=0.01).Significant differences were not observed
among carriers of the CYP17 TT genotype or CYP17 TC
genotypes with TD and carriers of these genotypes with-
out TD.Two way analysis of variance (ANOVA) with age
at first antipsychotic treatment as covariate showed a sig-
nificant main effect of DRD3 genotype on AIMS total
score (F=14.9,df=1,106,P=0.0002).There was no main
effect of CYP17 genotype on the AIMS score.There was
a significant interaction between DRD3 and CYP17
genotype on AIMS total score (F=4.2,df=2,106,P=0.02).
Figure 6 shows adjusted mean AIMS scores (derived
from analysis of covariance [ANCOVA]) for the patients
grouped according to DRD3 and CYP17 genotype.Post-
hoc Newman-Keuls tests showed that the highest AIMS
total (P<0.03) was in patients carrying the DRD3 gly9
allele and the CYP17 CC genotype.
Another gene–gene interaction reported in relation 
to TD involved DRD3 and cytochrome P450 1A2
Clinical research
90
Figure 5. Abnormal Involuntary Movements Scale (AIMS) orofacial dysk-
inesia scores among patients carrying: 5-HT2C-cys and DRD3-
ser alleles (both wild type); 5-HT2C-cys and DRD3-gly (wild
type + mutant); 5-HT2C-ser and DRD3-ser (mutant +wild
type); or, 5-HT2C-ser and DRD3-gly (mutant + mutant).
*P<0.05 versus 5-HT2C-cys and DRD3-ser (both wild type).
#P<0.05 versus 5-HT2-cys and DRD3gly (wild type + mutant). 
Reproduced from reference 16: Segman RH, Heresco-Levy U, Finkel B,
et al. Association between the serotonin 2C receptor gene and tardive
dyskinesia in chronic schizophrenia; additive contribution of 5-HT2Cser
and  DRD3gly alleles to susceptibility. Psychopharmacology.
2000;152:408-413. Copyright © Springer 2000.
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Figure 6. Interactive effect of DRD3 and CYP17 genes on Abnormal
Involuntary Movements Scale (AIMS) scores according to
DRD3 ser9gly and CYP17 genotype. Left: patients homozy-
gous for the DRD3 ser allele; right: carriers of the DRD3 gly
allele (heterozygotes and homozygotes). There is a significant
main effect of DRD3 genotype on AIMS total score (F=14.9,
df=1.106, P=0.0002) and a significant interaction between
DRD3 and CYP17 genotype (F=4.2, df=2,.106, P=0.02).
*P=0.03, post-hoc Newman-Keuls test.
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14(CYP1A2).Both genes had been found to be indepen-
dently associated with schizophrenia.
19 Basile et al
19 fur-
ther found that those patients who exhibited the risk
genotype at both DRD3 (gly9/gly9) and at CYP1A2
(CC) had the most severe TD, whereas those who had
only one risk genotype (gly9/gly9 or CC) demonstrated
intermediate severity of TD.Those patients who did not
have any risk genotypes at either locus demonstrated the
lowest mean TD severity scores on the AIMS scale
(P<0.00007).
A more recent report of gene–gene interaction confer-
ring susceptibility to TD concerns the functional ala9val
polymorphism in exon 2 of the magnesium superoxide
dismutase gene (MnSOD).MnSOD is one of three iso-
forms of superoxide dismutase (SOD) that are important
as antioxidants in protecting cells from the deleterious
effects of free radicals.The ala9 variant is associated with
less efficient functional activity of the enzyme.Hori et al
20
found a small but significant increase in the wild type val
allele in Japanese schizophrenia patients with TD,sug-
gesting that the ala allele may be protective against free
radical damage in TD.This finding was not replicated by
Zhang et al
21 in Chinese schizophrenia patients with TD.
However,in a subsequent report Zhang et al
22 found that
the val-val genotype was in fact associated with TD,but
only in those patients who were carriers of the gly allele
of the DRD3 ser9gly polymorphism.
We examined association of the ala9val polymorphism of
MnSOD with TD in Israeli schizophrenia patients and
also tested for an interaction between this polymorphism
and the DRD3 ser9gly polymorphism (Segman et al,
unpublished data).Patients were grouped according to
whether they were carriers of the ala allele of MnSOD,
the gly allele of DRD3,both,or neither.This grouping
takes into account an effect of DRD3 gly to increase sus-
ceptibility and a protective effect of MnSOD ala and
anticipates that patients carrying DRD3 gly and lacking
MnSOD ala will be most susceptible to TD and will have
the most severe abnormal involuntary movements.This
is indeed the case.The MnSOD-val DRD3-gly genotype
combination was the most frequent among patients with
TD (64%) and the MnSOD-ala DRD3-ser genotype
(24%) was the least frequent.Among patients without
TD the pattern was reversed.The most frequent geno-
type combination was MnSOD-ala\ DRD3-ser (76%)
and the least frequent combination was MnSOD-val
DRD3-gly (38%, χ
2=10.5, df=3, P=0.01). Table I shows
that patients with the MnSOD-val\ DRD3-gly genotype
combination have the highest AIMS total scores and
patients with the MnSOD-ala DRD3-ser genotype com-
bination have the lowest (F=6.16;df=3,102;P=0.0007).
Prospects for pharmacogenetic 
testing in the clinic
The aim of pharmacogenetic research is to develop clin-
ically useful tests that will allow potential responders to
a particular psychotropic agent to be identified prospec-
tively, as well as those individuals likely to develop
adverse effects.This is not an easy task in the case of psy-
chotropic drugs.Some of the reasons for this difficulty
are applicable to drugs used to treat other complex dis-
orders;others are specific to psychotropic agents.Several
have been discussed in this paper.
The polygenic basis of pharmacogenetic traits is an issue
of major importance. For most traits it is unclear how
many genes are involved, and genes that have been
implicated thus far in well-studied phenotypes such as
TD are of small effect.The OR observed rarely exceed
2.0, and for the most part are less than 1.5. It requires
large samples to explore such small gene effects in the
definitive fashion required for their inclusion in a phar-
macogenetic test.Large samples are also needed in order
to tease apart gene–gene and gene–environment inter-
actions.Recruitment of large samples inevitably increases
the likelihood of stratification,which can lead to spuri-
ous results and must be taken into account.A further
consideration is that background and demographic vari-
ables must be considered (as pointed out in this paper for
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Table I. Abnormal involuntary movements assessed by the Abnormal
Involuntary Movements Scale (AIMS) in patients with chronic schiz-
ophrenia, grouped according to magnesium superoxide dismutase
(MnSOD) and dopamine D3 receptor (DRD3) genotype combina-
tions. MnSOD-ala/DRD3-ser: MnSOD ala9 allele carriers (ala-ala
homozygotes and ala-val heterozygotes), DRD3 ser9 homozygotes;
MnSOD-ala/DRD3-gly: MnSOD ala9 allele carriers, DRD3 gly9 carri-
ers (ser-gly heterozygotes and gly-gly homozygotes);  MnSOD
val/DRD3-ser: MnSOD val9 homozygotes, DRD3 ser9 homozygotes;
MnSOD val/DRD3-gly: MnSOD val9 homozygotes, DRD3 gly9 car-
riers. By analysis of variance (ANOVA): F=6.16; df=3,102; P=0.0007
*P=0.0004 vs MnSOD-ala/DRD3-ser; P=0.046 vs MnSOD-ala/DRD3
gly (post-hoc Newman-Keuls test) SD, standard deviation.
Genotype combination N AIMS total score SD
MnSOD-ala/DRD3-ser 29 2.6 2.7
MnSOD-ala/DRD3-gly 47 5.7 5.4
MnSOD-val/DRD3-ser 9 7.0 6.6
MnSOD-val/DRD3-gly 21 9.2 7.9*the role of age in the manifestation of certain gene effects
in TD) as well as treatment-related variables such as
medication dose,duration of treatment,and age at onset
of treatment. Furthermore, treatment outcome is fre-
quently related to severity of illness,and this must also
be taken into consideration.Thus,it is clear that a model
used to predict treatment outcome or susceptibility to
adverse effects will be unavoidably complex,given the
number of background and potential predicting variables
that will need to be taken into account including
gene–gene and gene–environment interactions.
Based on our previous work on the genetics of TD,we
have developed a preliminary model that takes into
account the various,background,clinical and genetic fac-
tors that we have studied (Segman et al, unpublished
data).We employed logistic regression and entered back-
ground and clinical variables known to influence sus-
ceptibility to TD such as age,sex,cigarette-smoking,age
at first antipsychotic treatment,duration of antipsychotic
treatment,antipsychotic dose in chlorpromazine units,
and total score on the Positive And Negative Syndrome
Scale (PANSS). The genetic variables included were
DRD3 gly9 allele carrier status,MsSOD ala9 allele car-
rier status, HTR2C ser23 allele carrier status, CYP17
genotype and HTR2A genotype.Interactions were also
tested for inclusion,but none were retained in the final
model. The overall model (Table II) was significant
(r
2=0.32;P=0.0005).The variables that significantly pre-
dicted TD within the model were age (OR=1.04,
P=0.047),PANSS total score (OR=1.02,P=0.014),DRD3
gly9 allele carrier status (OR=4.39, P=0.006), and
HTR2A 102CC genotype (OR=4.18,P=0.02).MNSOD
ala9 allele carrier status and HTR2C ser23 allele carrier
status were retained in the overall model,but were not
significant.In this manner,70.3% of cases could be cor-
rectly classified,compared with 60.2% prior to entry of
the variables.
The model described here is not sensitive enough to have
clinical utility.It is based on a single small sample of sub-
jects,and may not be generalizable to other samples and
populations. While recognizing these limitations, the
model does support the concept that a combination of
background,clinical,and genetic variables could poten-
tially be used to evaluate a priori the risk for TD in
patients treated with antipsychotic drugs that have the
potential to induce this adverse effect. This approach
could be extended to other pharmacogenetic phenotypes,
and ultimately allow the development of clinically viable
pharmacogenetic tests that will serve as the basis for a
rational assessment of cost-benefit ratios in the choice of
treatment with antipsychotics and other antipsychotic
drugs. ❏
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Table II. Logistic regression predicting tardive dyskinesia including background, clinical, and genetic variables. PANSS, Positive and Negative Syndrome
Scale; CI, confidence interval. *102TT genotype is reference category. Significant values highlighted in bold font.
Variable β SE Wald df P Odds ratio 95.0% CI
Lower Upper
Background variables
Age 0.04 0.02 3.93 1 0.047 1.04 1.00 1.08
Sex 0.20 0.49 0.16 1 0.686 1.22 0.47 3.15
Cigarette-smoking 0.14 0.46 0.09 1 0.766 1.15 0.47 2.83
Clinical variables
PANSS total score 0.02 0.01 6.00 1 0.014 1.02 1.00 1.03
Age at first antipsychotic treatment 0.05 0.03 2.37 1 0.124 1.05 0.99 1.11
Genetic variables
DRD3 gly9 allele 1.48 0.54 7.61 1 0.006 4.39 1.54 12.56
HTR2A T102C genotype 8.80 2 0.012
HTR2A 102CC genotype* 1.43 0.63 5.20 1 0.023 4.18 1.22 14.26
HTR2A 102TC genotype* -0.20 0.54 0.14 1 0.71 0.82 0.28 2.37
MNSOD ala9 allele -0.39 0.51 0.58 1 0.445 0.68 0.25 1.83
HTR2A ser23 allele -0.94 0.53 3.13 1 0.077 0.39 0.14 1.11
Constant -5.61 1.53 13.41 1 0 0Pharmacogenetics of antipsychotic therapy - Lerer and Segman Dialogues in Clinical Neuroscience - Vol 8 . No.1 . 2006
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Farmacogenética de la terapia antipsicótica:
temas clave de investigación y proyecciones
para la implementación clínica
La hipótesis central en que se fundamenta la fárma-
cogenética alude a que los factores genéticos tienen
un papel significativo en las diferencias bien reco-
nocidas entre los sujetos en la respuesta a los medi-
camentos y en la susceptibilidad a los efectos adver-
sos. Si estos factores genéticos pueden ser
identificados y comprendidos, ellos pueden servir
como predictores para guiar a los clínicos en la adap-
tación de la medicación al paciente individual.
Recientes desarrollos en el campo de la terapia antip-
sicótica sugieren que la farmacogenética podría
tener un importante papel, permitiendo el empleo
de antipsicóticos de primera generación (APG) en
pacientes en quienes la utilización de antipsicóticos
de segunda generación (ASG) está limitada por con-
sideraciones acerca de la eficacia o los efectos adver-
sos. En este artículo se discuten los temas clave que
necesitan ser tomados en cuenta al diseñar e inter-
pretar los estudios farmacogenéticos de los antipsi-
cóticos, frente al respaldo de datos que provienen de
estudios acerca de la genética de la disquinesia tar-
día (DT), un efecto adverso importante de los APG.
Los temas considerados incluyen las ventajas y poten-
ciales peligros de los estudios de asociación caso con-
trol de los rasgos farmacogenéticos, el papel de fac-
tores demográficos tales como edad y sexo, los
efectos aditivos de los genes y las interacciones entre
los genes (gen-gen) y de los genes con el ambiente.
También se han considerado las proyecciones para la
implementación de pruebas farmacogenéticas en la
clínica, en el contexto de un modelo preliminar que
ha sido probado para la predicción de susceptibili-
dad para la DT.
Pharmacogénétique du traitement 
antipsychotique : points essentiels de la
recherche et perspectives pour la 
réalisation clinique
Le rôle essentiel joué par le facteur génétique au
niveau des différences observées entre les individus
en réponse au traitement et à la susceptibilité vis-
à-vis des événements indésirables est la principale
hypothèse de la pharmacogénétique. Si ces facteurs
génétiques peuvent être identifiés et compris, ils
peuvent servir de guide aux médecins pour adap-
ter un traitement à chaque patient. Les développe-
ments récents dans le domaine du traitement anti-
psychotique suggèrent que la pharmacogénétique
pourrait jouer un rôle important, permettant l’uti-
lisation des antipsychotiques de première généra-
tion (APG) pour les patients chez qui l’utilisation
des antipsychotiques de seconde génération (ASG)
est limitée pour des raisons d’efficacité et d’événe-
ments indésirables. Dans cet article, nous parlerons
des points-clés qui doivent être pris en considéra-
tion pour concevoir et interpréter les études phar-
macogénétiques des antipsychotiques par rapport
à l’historique des données issues des études sur la
génétique des dyskinésies tardives (DT), événement
indésirable important des APG. Les questions étu-
diées comprennent les avantages et les embûches
potentielles des études d’association cas-témoins
des particularités pharmacogénétiques, le rôle des
facteurs démographiques tels que l’âge et le sexe,
les effets additifs des gènes et l’interaction gène-
gène et gène-environnement. On envisage les
perspectives de réalisation de l’expérimentation
pharmacogénétique en clinique dans le contexte
d’un modèle préliminaire déjà testé pour prévoir la
susceptibilité aux DT.
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